| Literature DB >> 29045233 |
Sadhna Verma1, Peter L Choyke1, Steven C Eberhardt1, Aytekin Oto1, Clare M Tempany1, Baris Turkbey1, Andrew B Rosenkrantz1.
Abstract
Systematic transrectal ultrasonography (US)-guided biopsy is the standard approach for histopathologic diagnosis of prostate cancer. However, this technique has multiple limitations because of its inability to accurately visualize and target prostate lesions. Multiparametric magnetic resonance (MR) imaging of the prostate is more reliably able to localize significant prostate cancer. Targeted prostate biopsy by using MR imaging may thus help to reduce false-negative results and improve risk assessment. Several commercial devices are now available for targeted prostate biopsy, including in-gantry MR imaging-targeted biopsy and real-time transrectal US-MR imaging fusion biopsy systems. This article reviews the current status of MR imaging-targeted biopsy platforms, including technical considerations, as well as advantages and challenges of each technique. © RSNA, 2017.Entities:
Mesh:
Year: 2017 PMID: 29045233 PMCID: PMC5673043 DOI: 10.1148/radiol.2017161684
Source DB: PubMed Journal: Radiology ISSN: 0033-8419 Impact factor: 11.105